These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 23199899)

  • 1. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
    Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
    Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
    Li L; Wang L; You QD; Xu XL
    J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic target Hsp90 and cancer hallmarks.
    Miyata Y; Nakamoto H; Neckers L
    Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
    Soga S; Akinaga S; Shiotsu Y
    Curr Pharm Des; 2013; 19(3):366-76. PubMed ID: 22920907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
    Hwang M; Moretti L; Lu B
    Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibitors targeting heat shock protein 90: An updated review.
    Li Y; Dong J; Qin JJ
    Eur J Med Chem; 2024 Sep; 275():116562. PubMed ID: 38865742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
    Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
    Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.
    Jhaveri K; Ochiana SO; Dunphy MP; Gerecitano JF; Corben AD; Peter RI; Janjigian YY; Gomes-DaGama EM; Koren J; Modi S; Chiosis G
    Expert Opin Investig Drugs; 2014 May; 23(5):611-28. PubMed ID: 24669860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 90 inhibitors as therapeutic agents.
    Gomez-Monterrey I; Sala M; Musella S; Campiglia P
    Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in Hsp90 inhibitors as antitumor agents.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Anticancer Agents Med Chem; 2008 Oct; 8(7):761-82. PubMed ID: 18855578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.
    Özgür A; Tutar Y
    Anticancer Agents Med Chem; 2016; 16(3):280-90. PubMed ID: 26295332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S; Bommaka MK; Banerjee A
    Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
    Isaacs JS
    Expert Opin Investig Drugs; 2005 Jun; 14(6):569-89. PubMed ID: 16004589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative approaches to Hsp90 modulation for the treatment of cancer.
    Hall JA; Forsberg LK; Blagg BS
    Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.